Why the study?
Does olmesartan improve atrial structural remodeling compared to azelnidipine in spontaneously hypertensive rats?
Does olmesartan improve atrial structural remodeling compared to azelnidipine in spontaneously hypertensive rats?
Olmesartan is more effective than azelnidipine in ameliorating atrial structural remodeling in spontaneously hypertensive rats, likely due to the suppression of oxidative stress.
Answers are grounded in this paper and cite their sources.
May favor ARBs over CCBs for atrial remodeling beyond BP control in models; leaves open human translation.
The differential effects between olmesartan (OM), an angiotensin 2 type 1 receptor blocker (ARB), and azelnidipine (AZ), a calcium channel blocker (CCB), on atrial structural remodeling were studied in spontaneously hypertensive rats (SHR). Eight weeks after treatment, both OM and AZ decreased systolic blood pressure to similar levels. Histological analysis revealed that both OM and AZ had decreased the size of the atrial myocytes and interstitial fibrosis in the atrium, and that the effects of OM were greater than those of AZ. These beneficial effects of OM were associated with less atrial oxidative stress, as assessed by 3-nitrotyrosine staining, and less activation of Rac1, a regulatory component in NADPH oxidase. These results suggest that the ARB was more effective than the CCB in ameliorating atrial structural remodeling due to the suppression of oxidative stress.
No takes yet. Share an insight, caveat, or question.
Okamura et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: